Theseus Pharmaceuticals price target lowered to $4 from $24 at Stifel

Stifel lowered the firm’s price target on Theseus Pharmaceuticals to $4 from $24 and keeps a Buy rating on the shares. The discontinuation of THE-630 after unfavorable safety in its dose-escalation study leaves some of the company’s programs without near-term data, attributing to the significant price target reduction, the analyst tells investors. Stifel maintains a Buy rating because competitor EGFRs can offer positive efficacy, the platform showcases the ability to generate “pan” variant coverage molecules, and the 2026 runway captures the first THE-349.